<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13402">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02066207</url>
  </required_header>
  <id_info>
    <org_study_id>146DDI13024</org_study_id>
    <nct_id>NCT02066207</nct_id>
  </id_info>
  <brief_title>CKD-337 Drug Interaction Study</brief_title>
  <official_title>Open-label, Randomized, Multiple-dose, Crossover Study to Evaluate the Pharmacokinetic Interaction Between Fenofibrate and Atorvastatin in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate a pharmacokinetic drug interaction between
      atorvastatin and fenofibrate in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>AUCt, Cmax,ss of fenofibric acid and atorvastatin</measure>
    <time_frame>0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 h</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss, Cmin,ss, t1/2, CL/Fss, Vd/Fss, %swing, Cav, %fluctuation</measure>
    <time_frame>0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48 h</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Dyslipidemia (Fredrickson Type Ⅱa)</condition>
  <condition>Dyslipidemia (Fredrickson Type Ⅱb)</condition>
  <arm_group>
    <arm_group_label>Fenofibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Fenofibrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Atorvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fenofibrate and Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Fenofibrate and Atorvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <arm_group_label>Fenofibrate</arm_group_label>
    <arm_group_label>Fenofibrate and Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_label>Fenofibrate and Atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A healthy male volunteer between 19 and 55 years old.

          -  BMI between 18.5 and 27.

          -  Able to participate in the entire trial

          -  Signed the informed consent form prior to study participation.

        Exclusion Criteria:

          -  Clinically significant digestive system, cardiovascular system, respiratory system,
             endocrine system, hepatic system, renal system

          -  sit SBP &lt; 100mmHg or sit SBP ≥ 150mmHg or sit DBP &lt; 70mmHg or sit DBP ≥ 100mmHg

          -  Have acute infection history within 14 days

          -  Have a allergic disease of need to treat

          -  Have hypersensitivity reactions history for IP or any specific drugs.

          -  AST, ALT or Total bilirubin &gt; UNL * 1.5

          -  Estimated GFR &lt; 60 ml/min

          -  Genetic problems such as galactose intolerance, Lapp lactase deficiency,
             glucose-galactose malabsorption

          -  A heavy smoker (cigarette &gt; 10 cigarettes per day)

          -  A heavy alcohol consumer (alcohol &gt; 140g/week)

          -  A heavy grapefruit consumer (more than 1cup per a day)

          -  Have a history of drug abuse or showed a positive for urine drug test.

          -  Administrated IP within 60 days prior to screening

          -  Rhabdomyolysis include of having a history or family history of genetic muscle
             diseases

          -  Positive for HIV antibody, HBsAg, HCV antibody test

          -  Previously donate whole blood within 60 days or component blood within 30 days

          -  Subject takes ethical drug or herbal medicine within 30 days

          -  Clinically significant laboratory test result

          -  An impossible one who participates in clinical trial by investigator's decision
             including other reason
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wooseong Huh, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wooseong Huh, M.D., Ph.D.</last_name>
    <phone>+82-2-3410-3443</phone>
    <email>wooseong.huh@samsung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wooseong Huh, M.D., Ph.D.</last_name>
      <phone>+82-2-3410-3443</phone>
      <email>wooseong.huh@samsung.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>February 18, 2014</lastchanged_date>
  <firstreceived_date>February 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
